Summary
Plasma growth hormone (GH) concentrations in Parkinsonian patients following 3 months optimum therapy with bromocriptine showed no significant change from pretreatment values, whilst plasma prolactin concentrations were uniformly suppressed. Pretreatment GH and prolactin levels were unrelated to clinical disability, and no correlation between hormonal changes and therapeutic response was found. These results suggest the presence of different dopaminergic receptor mechanisms for GH and prolactin release as well as between the extrapyramidal and neuroendocrine systems.
This is a preview of subscription content, log in via an institution to check access.
References
Boyd, A. E., Lebovitz, H. E., Pfeiffer, J. B. Stimulation of Human Growth Hormone Secretion by L-dopa. New England Journal of Medicine283, 1425–1429 (1970).
Boyd, A. E., Lebovitz, H. E., Feldman, J. M. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-dopa. Journal of Clinical Endocrinology33, 829–837 (1971).
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., Petrie, A. Bromocriptine in Parkinsonism. British Medical Journal4, 442–444 (1974).
Camanni, F., Massara, F., Belforte, L., Molinatti, G. M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-brom-α-ergocryptine. Journal of Clinical Endocrinology and Metabolism40, 363–366 (1975).
Cavagnini, F., Peracchi, M., Scotti, G., Raggi, V., Pontiroli, A. E., Band, R. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients. Journal of Endocrinology54, 425 to 433 (1972).
Chase, T. N., Woods, A. C., Lipton, M. A., Morris, C. E. Hypothakmic releasing factors and Parkinson's disease. Archives of Neurology31, 55–56 (1974).
Cotzias, G. C., Papavasiliou, P. S., Tolosa, E. S., Mendes, J. S., Bell-Midura, M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. New England Journal of Medicine294, 567–572 (1976).
Debono, A. G., Jenner, P., Marsden, C. D., Parkes, J. D., Tarsy, D., Walters, J. Plasma dopa levels and growth hormone response to levodopa in Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry40, 162–167 (1977).
Editorial: Bromocriptine. Lancet1, 1076 (1975).
Franks, S., Murray, M. A. F., Jequier, A. M., Steele, S. J., Nabarro, J. D. N., Jacobs, H. S. Incidence and significance of hyperprolactinaemia in women with amenorrhoea. Clinical Endocrinology4, 597–607 (1975).
Horrobin, D. F. Parkinsonism, Growth Hormone and Prolactin294, 1347 (1976).
Lees, A. J., Shaw, K. M., Stern, G. M. Bromocriptine in Parkinsonism. Lancet2, 709–710 (1975).
Lees, A. J., Shaw, K. M., Haddad, S., Kohout, L., Stern, G. M. Bromocriptine in Parkinson's disease—a longterm study. Archives of Neurology35, 503–505 (1978).
Malarkey, W. B., Jacobs, L. S., Daughhaday, W. H. Levodopa suppression in nonpuerperal galactorrhoea. New England Journal of Medicine285, 1160–1163 (1971).
Malarkey, W. B., Cyrus, J., Paulson, G. W. Dissociation of Growth Hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. Journal of Clinical Endocrinology and Metabolism39, 229–235 (1974).
McCaul, J. A., Cassell, K. J., Stern, G. M. Intravenous thyrotrophin-releasing hormone in Parkinson's disease. Lancet1, 735 (1974).
Mena, I., Cotzias, G. C., Brown, F. C., Papavasiliou, P. S., Miller, S. T. Defective release of growth hormone in Parkinsonism improved by levodopa. New England Journal of Medicine288, 320–321 (1973).
Nirsula, B. C., Glaubiger, G. A., Lou-vet, J., Chase, T. N. Effect of a large dose of thyrotrophin-releasing factor on pituitary and thyroid function in patients with Parkinsonism. Clinical Endocrinology5, 651–655 (1976).
Parkes, J. D., Marsden, C. D., Donaldson, I., Debono, A. E., Walters, J., Kennedy, G., Asselman, P. Bromocriptine treatment in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry39, 184 to 193 (1976 a).
Parkes, J. D., Debono, A. G., Marsden, C. D. Growth hormone response in Parkinson's disease. Lancet1, 483–484 (1976 b).
Parkes, J. D., Debono, A. G., Marsden, C. D. Bromocriptine in Parkinsonism: longterm treatment, dose response and comparison with levodopa. Journal of Neurology, Neurosurgery and Psychiatry39, 1101 to 1108 (1976 c).
Plotnikoff, N. P., Prange, A. J., Breese, G. R., Anderson, M. S., Wilson, C. Thyrotrophin-releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science178, 417–418 (1972).
Riese, W. Milchsekretion und Zwischenhirn. Klinische Wochenschrift41, 1954–1955 (1928).
Shaw, K. M., Lees, A. J., Hayes, S., Ross, E. J., Stern, G. M.: Growth hormone response to bromocriptine in Parkinsonism. Lancet 1,194 (1976).
Sirtori, C. R., Bolme, P., Azarnoff, D. L. Metabolic responses to L-dopa dministration in patients with Parkinsonism. New England Journal of Medicine287, 729–733 (1972).
Spaulding, S. W., Burrow, G. N., Donabedian, R., Van Woert, M. L-dopa suppression of thyrotrophin-releasing hormone response in man. Journal of Clinical Endocrinology and Metabolism35, 182–185 (1972).
Tang, L. C., Cotzias, G. C. Modification of the action of some neuroactive drugs by growth hormone. Archives of Neurology33, 131–134 (1976).
Thorner, M. O. Dopamine is an important neurotransmitter in the autonomie system. Lancet1, 662–664 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shaw, K.M., Lees, A.J., Franks, S. et al. Endocrine aspects of bromocriptine therapy in Parkinsonism. J. Neural Transmission 43, 153–160 (1978). https://doi.org/10.1007/BF01579074
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01579074